Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4774932 | 0.86 | CYP3A4 (0.45) | CYP3A4TRPA1ALDH1A1HPGDTDP1 | |
| SCHEMBL5788029 | 0.86 | CYP3A4 (0.45) | CYP3A4TRPA1ALDH1A1HPGDTDP1 | |
| SCHEMBL31401921 | 0.83 | CYP3A4 (0.35) | CYP3A4TRPA1ALDH1A1HPGDTDP1 | |
| SCHEMBL4350030 | 0.79 | ALDH1A1 (0.31) | CYP3A4ALDH1A1HPGDTDP1 | |
| SCHEMBL707228 | 0.78 | CYP3A4 (0.55) | CYP3A4TRPA1ALDH1A1HPGDTDP1 | |
| SCHEMBL4774935 | 0.78 | CYP3A4 (0.36) | CYP3A4TRPA1 | |
| SCHEMBL1647291 | 0.77 | CES2 (0.39) | CYP3A4TRPA1ALDH1A1HPGDTDP1 | |
| SCHEMBL31448284 | 0.77 | CES2 (0.39) | CYP3A4TRPA1ALDH1A1HPGDTDP1 | |
| SCHEMBL11362110 | 0.76 | CES2 (0.31) | — | |
| SCHEMBL8116818 | 0.74 | CES2 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10112954-B2 | Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase | HANMI PHARM. CO., LTD. (KR) | 2018-10-30 | — | — | US | disclosed |
| EP-2945950-B1 | ISOMANNIDE DERIVATIVES AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | SANOFI SA (FR) | 2017-03-01 | — | — | EP | disclosed |
| EP-2791111-B1 | [4-(PIPERIDIN-4-YL)-NAPHTHALEN-2-YL]-ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS FOR THE TREATMENT OF RESPIRATORY DISORDERS | HOFFMANN LA ROCHE (CH) | 2017-01-18 | — | — | EP | disclosed |
| EP-2877480-A1 | GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS | Universiteit van Gent (BE) | 2015-06-03 | — | — | EP | disclosed |
| US-8962637-B2 | Bicyclic compounds and their uses as dual c-SRC/JAK inhibitors | DEBIOPHARM S.A. (CH) | 2015-02-24 | — | — | US | disclosed |
| EP-2791111-A1 | PIPERIDINYL NAPHTHYLACETIC ACIDS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-10-22 | — | — | EP | disclosed |
| EP-2536722-B1 | BICYCLIC COMPOUNDS AND THEIR USES AS DUAL C-SRC / JAK INHIBITORS | DEBIOPHARM SA (CH) | 2014-04-16 | — | — | EP | disclosed |
| WO-2014001204-A1 | GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS | UNIVERSITEIT GENT (BE) | 2014-01-03 | — | — | WO | disclosed |
| WO-2013087544-A1 | PIPERIDINYL NAPHTHYLACETIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-20 | — | — | WO | disclosed |
| US-20130150407-A1 | PIPERIDINYL NAPHTHYLACETIC ACIDS | HOFFMANN-LA ROCHE INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-6750233-B2 | SELECTIVITY | PHARMACIA CORPORATION | 2004-06-15 | — | — | US | disclosed |
| EP-0848023-B1 | Low surface energy polyisocyanates and their use in one- or two-component coating compositions | BAYER AG (US) | 2003-08-27 | — | — | EP | disclosed |
| EP-1183239-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000069821-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2000-11-23 | — | — | WO | disclosed |
| WO-1999020617-A1 | ANTIINFLAMMATORY THIADIAZOLYL UREAS WHICH ACT AS LFA-1 AND MAC-1 INHIBITORS | ACTIVE BIOTECH AB (SE) | 1999-04-29 | — | — | WO | disclosed |
| EP-0848023-A1 | Low surface energy polyisocyanates and their use in one- or two-component coating compositions | Bayer Corporation (US) | 1998-06-17 | — | — | EP | disclosed |
| US-5747629-A | Low surface energy polyisocyanates and their use in one-or two-component coating compositions | BAYER CORPORATION (US) | 1998-05-05 | — | — | US | disclosed |
| EP-0682656-A1 | USE OF PHENYL HETEROARYL UREAS AS 5HT 2C? RECEPTOR ANTAGONISTS AND UREA COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 1995-11-22 | — | — | EP | disclosed |
| WO-1994018170-A1 | USE OF PHENYL HETEROARYL UREAS AS 5HT2C RECEPTOR ANTAGONISTS AND UREA COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 1994-08-18 | — | — | WO | disclosed |
| EP-0348350-A1 | Heteroatom containing perfluoroalkyl terminated neopentyl glycols and polymers therefrom | CIBA-GEIGY AG (CH) | 1989-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10112954-B2 | Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase | CDK2, SBK3, CDK2AP1 | CYP3A4 3643/4885TRPA1 3926/4885ALDH1A1 3711/4885 |
| US-20130150407-A1 | PIPERIDINYL NAPHTHYLACETIC ACIDS | HRH2, HRH1, HRH3 | CYP3A4 2277/4885TRPA1 231/4885ALDH1A1 481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.